Why wait to prescribe TRELEGY for your patients with ASTHMA who remain symptomatic on an ICS/LABA?
Meet
CRAIG
a patient with ASTHMA
40-year-old adherent on a
MEDIUM-DOSE ICS/LABA

Symptomatic with ASTHMA
Chest tightness
Shortness of breath once a week
Nighttime symptoms at least
once a weekAs-needed SABA use
Meet
LIZ
a patient with ASTHMA
48-year-old treated with a
HIGH-DOSE ICS/LABA

Symptomatic with ASTHMA
Daily shortness of breath
An exacerbation requiring a short
course of oral corticosteroidsIncreased SABA use

You may have patients who remain symptomatic with current ASTHMA therapy

Of patients with ASTHMA treated with a medium- or high-dose ICS/LABA,
30% - 50%
reported inadequately controlled ASTHMA (ACT ≤19) even
when treatment adherence was optimal1-5
Based on data from 3 randomized controlled trials (N=2431) and a real-world study (N=428). For the randomized controlled trials, >90% of patients were >80% adherent. For the real-world study, only patients with self-reported moderate to high adherence according to the MMAS were included.1-5
The 2021 GINA Report includes single-inhaler triple therapy as a preferred controller option for adult patients with ASTHMA who are not well controlled on a medium- or high-dose ICS/LABA.6

Uncovering unreported
symptoms
Careful questioning may reveal
poorly controlled ASTHMA, so
look for:
- Frequency of ASTHMA symptoms6
- Any limitations to activities6
- Nighttime awakenings6
- How often the patient refills rescue
medication6
A short test to assess ASTHMA
control
Learn about a tool to help track ASTHMA
control in your patients.
Identify undertreated patients with
ASTHMA earlier
Undertreated ASTHMA can lead to uncontrolled symptoms, loss of lung function, and exacerbations.6


See TRELEGY efficacy data vs
an ICS/LABA in adults with
ASTHMA.